In the PRODIGE 59 DURIGAST trial, 97 patients with metastatic HER2-positive gastric or GEJ adenocarcinoma underwent serial ctDNA monitoring using a tumor-agnostic methylation-based ddPCR assay (TriMeth) and amplicon-based NGS [67]. The gene discussed is ERBB2; the disease is neoplasm.